MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium



    
    Site to Provide Glucotrace (Fluorodeoxyglucose) for Use in Earlier
    Detection of Disease and Therapy Management
    

    OTTAWA and FLEURUS, Belgium, May 28 /CNW/ - MDS Nordion, a leading global
provider of medical isotopes and radiopharmaceuticals used in molecular
medicine, today announced the opening of a facility in Fleurus, Belgium for
the production of Glucotrace (Fluorodeoxyglucose), a radiopharmaceutical used
in positron emission tomography (PET) imaging.
    PET imaging produces a three-dimensional image, or picture, of functional
processes in the body, such as brain activity, and is a highly accurate and
effective method of diagnosing disease and managing patient therapy. MDS
Nordion's new facility will provide timely supply of Glucotrace to hospitals
throughout Belgium, France, The Netherlands, Luxembourg and Germany.
    "Customers count on MDS Nordion for leadership, quality products and
customized services," said Steve West, President MDS Nordion. "Our investment
in this facility further demonstrates our commitment to address the growing
demand for PET diagnostic imaging in targeted European regions, and provides
the medical community greater service for their future patient care."
    The PET imaging market is the most rapidly growing area of nuclear
medicine and procedures. Statistics from a recent Medical Options survey
indicates PET examinations are on a rapid rise in Europe, and are expected to
grow at a compound annual rate of approximately 20% through 2012. To help meet
increasing demand, this state-of-the-art, Good Manufacturing Practice (GMP)
production facility will have three daily production runs and a customer
service team available 24 hours a day, seven days a week.
    "PET imaging is effective because it allows early detection of tumours,
as well as assessment of therapeutic strategies," said Professor Roland
Hustinx, Nuclear Medicine Department, CHU - Université de Liège. "In
particular, MDS Nordion's new facility will provide another source of supply
of Glucotrace to existing and new medical facilities, thereby increasing the
ability of health-care practitioners to conduct this critical type of
imaging."

    About MDS Nordion

    MDS Nordion, a business unit of MDS Inc., is a global leader in providing
medical isotopes for molecular and diagnostic imaging, radiotherapeutics and
sterilization technologies for medical products that benefit the lives of
millions of people in more than 50 countries around the world. MDS Nordion's
products and services are used on a daily basis by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals, clinics and
research laboratories. Find out more at www.mdsnordion.com.

    About MDS

    MDS Inc. (TSX: MDS; NYSE:   MDZ) is a global life sciences company that
provides market-leading products and services that our customers need for the
development of drugs, and the diagnosis and treatment of disease. We are a
leading global provider of pharmaceutical contract research, medical isotopes
for molecular imaging, radiotherapeutics, and analytical instruments. MDS has
more than 5,000 highly skilled people in 29 countries. Find out more at
www.mdsinc.com.





For further information:

For further information: CONTACT MDS Nordion: MEDIA: Shelley Maclean,
(613) 291-3689, shelley.maclean@mdsinc.com; INVESTORS: Kim Lee, (416)
213-4721, kim.lee@mdsinc.com

Organization Profile

MDS NORDION

More on this organization

Nordion Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890